Leukapheresis in remission induction and steroid withdrawal in steroid-dependent ulcerative colitis;Aféresis leucocitaria en la inducción de la remisión y retirada de corticoides en la colitis ulcerosa corticodependiente

Dialisis y Trasplante

Volumn 28, Issue 2, 2007, Pages 47-55

  Cabriada Nuño, José Luis ^a   Bernal Martínez, Antonio ^a   Hernández Martín, Anaiansi ^a   Arévalo Serna, Juan Antonio ^a   Fernández Prado, Encarnación ^a  

^a HOSPITAL DE GALDAKAO   (Spain)

Author keywords

Immunomodulators; Leukapheresis; Steroid dependent ulcerative colitis

Indexed keywords

IMMUNOMODULATING AGENT; STEROID;

ARTICLE; CANNULATION; CENTRAL VENOUS CATHETER; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG WITHDRAWAL; ENDOSCOPY; HUMAN; LEUKAPHERESIS; PNEUMOTHORAX; REMISSION; ULCERATIVE COLITIS;

EID: 34547738548     PISSN: 18862845     EISSN: 18867278     Source Type: Journal    
DOI: 10.1016/S1886-2845(07)71352-8     Document Type: Article

References (35)

1. Faubion WA, Loftus EV, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatoty bowel disease:a population-based study. Gastroenterology. 2001;121:255-60.
2. Rutgeerts P. Review article: the limitations of corticosteroid therapy in Crohn's disease. Aliment Pharmacol Ther. 2001;15:1515-25.
3. Pearson DC, May GR, Fick G, Sutherland LR. Azathioprine for maintaining remission of Crohn's disease. En: The Cochrane Library, Issue 2; 2001. Oxford: Update Software; 2000.
4. López-Sanromán A, Bermejo F, Carrera E, García-Plaza A. Efficacy and safety of thiopurinic immunomodulators (azathioprine and mercaptopurine) in steroid-dependent ulcerative colitis. Aliment Pharmacol Ther. 2004;20:161-6.
5. Rutgeerts P, Sandborn W, Feagan B, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462-76.
6. Colombel JF, Loftus EV, Tremaine WJ, Egan LJ, Harmsen WS, Schleck CD, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo Clinic experience in 500 patients. Gastroenterology. 2004;126:19-31.
7. McCarthy DA, Rampton DS, Liu YC. Peripheral blod neutrophils in inflammatory bowel disease: morphological evidence of in vivo activation in active disease. Clin Exp Immunol. 1991;86:489-93.
8. Sandborn W. Preliminary data on the use of apheresis in inflammatory bowel disease. Inflamm Bowel Dis. 2006;12:S15-21.
9. Tibble JA, Sigthorson G, Bridger D. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology. 2000;119:15-22.
10. Sawada K. Leukocytapheresis as an adjunct to conventional medication for inflammatory bowel disease. Dis Colon Rectum. 2003;46:S66-77.
11. Hanai H, Watanabe F, Takeuchi K, Iida T, Yamada M, Iwaoka Y, et al. Leukocyte adsorptive apheresis for the treatment of active ulcerative colitis: a prospective, uncontrolled, pilot study. Clin Gastroenterol Hepatol. 2003;1:28-35.
12. Kashiwagi N, Sugimura K, Koiwai H, Yamamoto H, Yoshikawa T, Saniabadi A, et al. Immunomodulatory effects of granulocyte and monocyte adsorption apheresis as a treatment for patients with ulcerative colitis. Dig Dis Sci. 2002;47:1334-41.
13. Mitsuyama K, Suzuki A, Matsumoto S, Tomiyasu N, Takaki K, Takedatsu J, et al. Diminished cytokine signalling against bacterial components in mononuclear leucocytes from ulcerative colitis patients after leukocytapheresis. Clin Exp Immunol. 2005;141:130-40.
14. Hanai H, Watanabe F, Yamada M, Sato Y, Takeuchi K, Iida T, et al. Correlation of serum soluble TNF-α receptors I and II levels with disease activity in patients with ulcerative colitis. Am J Gastroenterol. 2004;99:1532-8.
15. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol. 1989;24:2-6.
16. Nos P, Hinojosa J. Criterios diagnósticos. En: Conductas de actuación en la enfermedad inflamatoria crónica intestinal. Madrid: Adalia; 2003. p. 9-22.
17. Fernández Blanco JI, Gomollón F. Índices de actividad en la colitis ulcerosa. En: Gassull MA, Gomollón F, Obrador A, Hinojosa J, editores. Enfermedad Inflamatoria Intestinal. Madrid: Ergón; 2002. p. 111-24.
18. Rachmilewitz D. Coated mesalazine (5-amino-salicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ. 1989;298:82-6.
19. Saniabadi A, Hanai H, Takeuchi K, Umemura K, Nakashima M, Adachi T, et al. Adacolumn, an adsorptive carrier based granulocyte and monocyte apheresis device for the treatment of inflammatory and refractory diseases associated with leukocytes. Ther Apher Dial. 2003;7:48-59.
20. Sawada K, Muto T, Shimoyama T, Satomi M, Sawada T, Nagawa H, et al. Multicenter randomized controlled trial for the treatment of ulcerative colitis with a leukocytapheresis column. Curr Pharm Des. 2003;9:307-21.
21. Kruis W, Dignass A, Steinhagen-Thiessen E, Morgenstern J, Mossner J, Schreiber S, et al. Open label trial of granulocyte apheresis suggests therapeutic efficacy in chronically active steroid refractary ulcerative colitis. World J Gastroenterol. 2005;11:7001-6.
22. Hanai H, Watanabe F, Yamada M, Sato Y, Takeuchi K, Iida T, et al. Adsortive granulocyte and monocyte apheresis versus prednisolone in patients with corticosteroid-dependent moderately severe ulcerative colitis. Digestion. 2004;70:36-44.
23. Sawada K, Hiwatashi N, Munakata A, Asakura H, Suzuki Y, Muto T, et al. A multicentre randomized controlled study of safety and efficacy of adsorptive granulocyte and monocyte apheresis in patients with active ulcerative colitis. Gastroenterology. 2004;126:A462.
24. Sawada K, Kusugami K, Suzuki Y, Bamba T, Munakata A, Hibi T, et al. Leukocytapheresis in ulcerative colitis:results of a multicenter double-blind prospective case-control study with sham apheresis as placebo treatment. Am J Gastroenterol. 2005;100:1362-9.
25. Cabriada JL, Domènech E, Gomollón F, González-Carro P, González-Lara V, Hinojosa J, et al. Documento de consenso en el uso de la granulocitoaféresis en pacientes con enfermedad inflamatoria intestinal. Gastroenterol Hepatol. 2006;29:85-92.
26. Naganuma M, Funakoshi S, Sakuraba A, Takagi H, Inoue N, Ogata H, et al. Granulocytapheresis is useful as an alternative therapy in patients with steroid-refractory or -dependent ulcerative colitis. Inflamm Bowel Dis. 2004;10:251-7.
27. Kanke K, Nakano M, Hiraishi H, Terano A. Clinical evaluation of granulocyte/monocyte apheresis therapy for active ulcerative colitis. Dig Liver Dis. 2004;36:811-7.
28. Doménech E, Hinojosa J, Esteve-Comas M, Gomollón F, Herrera JM, Bastida G, et al. Granulocyteapheresis in steroid-dependent inflammatory bowel disease: a prospective, open, pilot study. Aliment Pharmacol Ther. 2004;20:1347-52.
29. Yamamoto T, Umegae S, Kitagawa T, Yasuda Y, Yamada Y, Takahasi D, et al. Granulocyte and monocyte adsorptive apheresis in the treatment of active distal ulcerative colitis: a prospective pilot study. Aliment Pharmacol Ther. 2004;20:783-92.
30. Panés J, Aceituno M, Domènech E, Hinojosa J. Aféresis leucocitaria en el tratamiento de la enfermedad inflamatoria intestinal. GH Continuada. 2005;4:227-32.
31. Sakuraba A, Sato T, Morohoshi Y, Iwao Y, Hibi T. Intensive therapy of granulocyte and monocyte adsorption apheresis induces rapid remission in patients with ulcerative colitis. Gut. 2004;Suppl 6:A231.
32. Ovidio VD, Aratari A, Viscido A, Marcheggiano A, Papi C, Capurso L, et al. Mucosal features and granulocyte-monocyte apheresis in steroid-dependent/ refractory ulcerative colitis. Dig Liver Dis. 2006;38:389-94.
33. Modesto I, Scimeca D, Orlando A, Cottone M. Leukocytapheresis in patients with moderate-severe steroid-dependant ulcerative colitis: clinical response without endoscopic response. Inflamm Bowel Dis. 2006;12:1009-10.
34. Nagase K, Sawada K, Ohnishi K, Egashira A, Ohkusu K, Shimoyama T. Complications of leukocytapheresis. Ther Apher. 1998;2:120-4.
35. Sands B, Sandborn W, Wolf D, Katz S, Safdi M, Schwartz D, et al. Pilot feasibility studies of leukocytapheresis with the Adacolumn apheresis system in patients with active ulcerative colitis or Crohn disease. J Clin Gastroenterol. 2006;40:482-9.